May 14, 2021 -- Biogen and Envisagenics have announced a new collaboration to advance RNA splicing research within central nervous system (CNS) diseases.
As part of the collaboration, Biogen will leverage Envisagenics' proprietary artificial intelligence-driven RNA splicing platform, SpliceCore, to define and understand the regulation of different RNA isoforms in CNS cell types.
The collaboration aims to identify, test, and validate splicing errors at scale. Biogen will gain access to SpliceCore's database of approximately 7 million potential RNA splicing errors, providing Biogen with a broader lens to evaluate splicing events that may be targeted for therapeutic gain.
Financial details of the collaboration were not disclosed.